EuroBiotech: More Articles of Note

Newspapers
Oncology Venture, which recently picked up a drug from Novartis, agreed to merge with Medical Prognosis Institute. (NS Newsflash/CC BY 2.0)

> Biogen paid Neurimmune $50 million (€42 million) to cut the royalty rate on potential future sales of Alzheimer’s candidate aducanumab by 5%. The transaction gives Swiss biotech Neurimmune a one-time cash boost today in exchange for less cash in the future if aducanumab bucks the odds and delivers positive data in phase 3. Statement

> C4X Discovery and e-Therapeutics teamed up to research novel ways to treat Parkinson’s disease. The collaboration builds on C4X’s work to identify genes associated with the disease. Release 

> Orchard Therapeutics received a rare pediatric disease designation from the FDA. The status covers the gene therapy specialist’s treatment of metachromatic leukodystrophy. Statement 

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> A-Mansia raised €13 million ($16 million). The first close of the series A round equips the Belgian microbiome startup to research active components isolated from the Akkermansia muciniphila bacterium. Release

> Oncology Venture, which recently picked up a drug from Novartis, agreed to merge with Medical Prognosis Institute. Statement   

> Glialign received seed funding to research a cell therapy for peripheral nerve repair. The UCL Technology Fund contributed to the financing. Release

Suggested Articles

Sumitovant CEO Myrtle Potter discusses the $3 billion Roivant-Sumitomo deal, her role at Sumitovant and what's up in 2020.

Antibiotics player Summit Therapeutics is gearing up for a new clinical trial of its lead asset, an antibiotic for Clostridium difficile infection.

In this week's EuroBiotech Report, Roche's risdiplam clears another phase 3 SMA trial, Merck KGaA spinout raises cash and Korean VCs back PDC*line.